Comparative Pharmacology
Head-to-head clinical analysis: HALOTHANE versus PROPOFOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTHANE versus PROPOFOL.
HALOTHANE vs PROPOFOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.
Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.
Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.
Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.
None Documented
None Documented
Clinical Note
moderateHalothane + Torasemide
"The risk or severity of adverse effects can be increased when Halothane is combined with Torasemide."
Clinical Note
moderatePropofol + Torasemide
"The risk or severity of adverse effects can be increased when Propofol is combined with Torasemide."
Clinical Note
moderateHalothane + Etacrynic acid
"The risk or severity of adverse effects can be increased when Halothane is combined with Etacrynic acid."
Clinical Note
moderatePropofol + Etacrynic acid
Terminal elimination half-life approximately 5-10 hours post-anesthesia, with a slower terminal phase (up to 3 days) due to redistribution from fat stores. Clinically, washout is rapid initially but prolonged exposure in obese patients may lead to detectable levels for days.
Terminal elimination half-life: 4-7 hours (after prolonged infusion, context-sensitive half-life increases up to 60 minutes after 8-hour infusion).
Primarily eliminated via pulmonary excretion (60-80% unchanged); approximately 20% metabolized in liver via CYP2E1, with metabolites excreted renally (trifluoroacetic acid, chloride, bromide). Only about 0.5% excreted unchanged in urine. Fecal excretion negligible.
Renal: <1% unchanged; hepatic metabolism to inactive glucuronide and sulfate conjugates, excreted renally (≈88%) and fecally (≈1-2%).
Category C
Category A/B
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Propofol is combined with Etacrynic acid."